WHO ICTRP trial
A study of the effectiveness and safety of the drug Pazopanib for use in…
EUCTR2011-001211-31-GB · EU Clinical Trials Register · Authorised
Key facts
| Trial ID | EUCTR2011-001211-31-GB |
|---|---|
| Public title | A study of the effectiveness and safety of the drug Pazopanib for use in patients with advanced kidney cancer who are suffering symptoms from their illness. |
| Scientific title | A study of pazopanib efficacy and safety in patients with advanced clear-cell renal cell carcinoma and ECOG Performance Status 2 (PaZ02) - Pazopanib in patients with renal cancer (PaZ02) |
| Primary sponsor | University of Birmingham |
| Registry | EU Clinical Trials Register |
| Recruitment status | Authorised |
| Study type | Interventional clinical trial of medicinal product |
| Countries | United Kingdom |
| Conditions | Clear cell renal cell carcinoma MedDRA version: 14.1 Level: LLT Classification code 10038416 Term: Renal clear cell carcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic… |
| Interventions | Trade Name: Votrient Product Name: pazopanib Product Code: not applicable Pharmaceutical Form: Film-coated tablet INN or Proposed INN: pazopanib hydrochloride CAS Number: 635702-64-6 Other descriptive name: Votrient Concentration unit: mg… |
| Registration date | Jan 24, 2012 |
| Target size | 75 |
| Secondary IDs | RG_10-177 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: